MAPT and Alzheimer disease: With the aim to detect cortical changes associated with early AD, our study has focused on testing acute Aβ42 effects, but we do not exclude the possibility that the tau mutation may also play a role in altering the functional activity of mPFC pyramidal neurons at early-stage and/or later-stage AD.